贝伐单抗联合AP方案治疗晚期非鳞非小细胞肺癌的疗效分析

Efficacy of Bevacizumab Combined with AP Scheme for Advanced Non-squamous Non-small Cell Lung Cancer

目的探讨贝伐单抗联合AP方案(培美曲塞/顺铂)治疗晚期非鳞非小细胞肺癌(NSCLC)的疗效。方法根据治疗方案将2010年1月-2011年4月江西省肿瘤医院收治的81例晚期非鳞NSCLC患者分为观察组(45例)与对照组(36例)。观察组治疗采用贝伐单抗联合AP方案,对照组治疗采用AP方案。结果 1观察组化疗近期疗效显著优于对照组(P<0.05)。2观察组与对照组中性粒细胞减少、血小板减少、呕吐、肝功能异常、肾功能异常等化疗不良反应分级相比差异无统计学意义(P>0.05)。3观察组中位无进展生存期(m PFS)、中位总生存期(m OS)显著高于对照组(P<0.05)。结论贝伐单抗联合AP方案治疗晚期非鳞NSCLC的近期疗效与远期疗效优于AP方案,且安全性好。

Objective To investigate the efficacy of bevacizumab and AP scheme ( pemetrexed plus cisplatin ) in the treatment of advanced non-squamous non-small cell lung cancer ( NSCLC ) .Methods 81 cases of advanced non-squamous NSCLC were divided into the observation group (45 cases) and the control group(36 cases).The observation group received bev-acizumab and AP scheme ,while the control group was given AP scheme only .Results ①The short-term efficacy of chemothera-py in the observation group was superior to control group (P<0.05).②No significant differences in the degree of neutropenia , thrombocytopenia,vomiting,hepatic dysfunction and renal dysfunction were found between the observation group and the control group(P>0.05).③The median progression-free survival time (mPFS) and median overall survival time(mOS) in the observa-tion group were significantly higher than those of the control group (P<0.05).Conclusion The short-term and long-term effi-cacy of bevacizumab and AP scheme ,which shows good safety ,are superior to AP scheme in the treatment of advanced non-squa-mous NSCLC .